GILD
USDGilead Sciences Inc. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$123.890
Kõrge
$124.000
Madal
$117.540
Maht
6.29M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
147.6B
Tööstusharu
Drug Manufacturers - General
Riik
United States
Kauplemisstatistika
Keskmine maht
6.96M
Börs
NMS
Valuuta
USD
52 nädala vahemik
Seotud uudised
Gilead Sciences to Present at Upcoming Investor Conferences
Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its executives will be speaking at the following investor conferences: UBS Global Healthcare Conference on Monday, November 10 at 11:00 AM Eastern
Truist Securities Reiterates Buy on Gilead Sciences, Raises Price Target to $145
Truist Securities analyst Asthika Goonewardene reiterates Gilead Sciences with a Buy and raises the price target from $127 to $145.
Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025
– Updated Results from Phase 2 Pivotal iMMagine-1 Study of Anito-cel for Relapsed/Refractory Multiple Myeloma to be Presented Orally – – New Findings Reinforce Yescarta's® Curative Potential as Second-Line
JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $150
JP Morgan analyst Chris Schott maintains Gilead Sciences with a Overweight and raises the price target from $145 to $150.
Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026
Gilead beats estimates, raises 2025 guidance, driven by strong HIV and liver drug sales and multiple launches planned for 2026.
RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $105
RBC Capital analyst Brian Abrahams maintains Gilead Sciences with a Sector Perform and raises the price target from $100 to $105.
Cantor Fitzgerald Reiterates Overweight on Gilead Sciences, Maintains $135 Price Target
Cantor Fitzgerald analyst Carter Gould reiterates Gilead Sciences with a Overweight and maintains $135 price target.
Seotud aktsiad
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.